World News

Kenmare Bio will obtain worldwide development and commercialization rights to an experimental oral small molecule known as FHND5032, with the exception of Greater China, where Chia Tai Feng Hai will retain control.

Eli Lilly will obtain exclusive global rights to advance these programmed recombinases through preclinical studies, clinical development, and eventual commercialization.

The investment will enhance AstraZeneca’s existing manufacturing sites in Wuxi, Beijing, Qingdao, and Taizhou, which already serve patients in China and across 70 international markets.

The AI-powered system automatically analyzes computed tomography (CT) scans that were originally performed for unrelated medical reasons, identifying osteoporotic pathological signs without requiring additional examinations.

Amplifai Health’s acceptance into this programme validates the company’s approach to implementing AI technology in practical healthcare settings where it can make an immediate difference in patient care.

Through this acquisition, Mirum gains worldwide rights to brelovitug, a monoclonal antibody that has advanced to Phase III clinical development.

The 22 national standards, which include two pre-standards developed in 2024, specifically address the safe deployment of AI technologies in medical environments.

The partnership between these companies stems from a late 2024 licensing agreement in which Corxel obtained worldwide rights to CX11, excluding China, from Vincentage.

The merger has already cleared several regulatory hurdles, having secured approval from the Competition Commission of India (CCI) and received ‘No Objection’ letters from the Stock Exchanges.

The grant will enable Qure.ai to develop a comprehensive open-source multi-modal database designed to accelerate future prevention and identification innovations.